Pharming Group (NASDAQ:PHAR - Get Free Report) saw an uptick in trading volume on Wednesday . 5,941 shares changed hands during mid-day trading, a decline of 5% from the previous session's volume of 6,240 shares.The stock last traded at $11.68 and had previously closed at $11.95.
Analyst Upgrades and Downgrades
A number of research firms have recently issued reports on PHAR. Oppenheimer boosted their price target on shares of Pharming Group from $30.00 to $39.00 and gave the company an "outperform" rating in a research note on Friday, March 14th. HC Wainwright reaffirmed a "buy" rating and set a $37.00 target price on shares of Pharming Group in a research note on Thursday, March 20th.
View Our Latest Analysis on Pharming Group
Pharming Group Stock Performance
The firm's 50 day moving average is $9.63 and its two-hundred day moving average is $9.16. The stock has a market capitalization of $739.57 million, a PE ratio of -41.81 and a beta of 0.02. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53.
Pharming Group (NASDAQ:PHAR - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.03. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. The firm had revenue of $79.09 million for the quarter, compared to the consensus estimate of $67.74 million. As a group, research analysts predict that Pharming Group will post -0.2 earnings per share for the current year.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Further Reading
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
